CD8A and cancer: For peptide-based cancer vaccines to be effective, they need both CD8+ epitopes, which can exploit antigen cross-presentation pathway and activate CTL antitumor immunity, and CD4+ epitopes, which can activate T-helper cells and maintain CTL effector activity [41].